The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: A plain language summary
Kopetz, S., Yoshino, T., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, … Read More
